Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gains from Investment Securities (2016 - 2026)

Insight Molecular Diagnostics' Gains from Investment Securities history spans 7 years, with the latest figure at -$1.1 million for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 73.92% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.9 million, a 62.47% decrease, with the full-year FY2025 number at $12000.0, down 98.9% from a year prior.
  • Gains from Investment Securities hit -$1.1 million in Q4 2025 for Insight Molecular Diagnostics, down from $3.4 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for IMDX hit a ceiling of $25.0 million in Q4 2021 and a floor of -$6.4 million in Q2 2022.
  • Historically, Gains from Investment Securities has averaged $2.7 million across 5 years, with a median of $444904.0 in 2021.
  • Biggest five-year swings in Gains from Investment Securities: soared 2527.77% in 2021 and later crashed 21296.67% in 2022.
  • Tracing IMDX's Gains from Investment Securities over 5 years: stood at $25.0 million in 2021, then plummeted by 30.97% to $17.3 million in 2022, then plummeted by 35.2% to $11.2 million in 2023, then plummeted by 138.22% to -$4.3 million in 2024, then skyrocketed by 73.92% to -$1.1 million in 2025.
  • Business Quant data shows Gains from Investment Securities for IMDX at -$1.1 million in Q4 2025, $3.4 million in Q3 2025, and $2.8 million in Q2 2025.